Company: BLTE
Filing Date: 2025-12-02
Form Type: 424B5
Source: 0001104659-25-117702
Chunk: 0

Company: BELITE BIO, INC
Filing Date: 2025-12-02
Form: 424B5
Chunk 0
---
**TABLE OF CONTENTS

Filed Pursuant to rule 424(b)(5)
Registration No. 333-284521 PROSPECTUS SUPPLEMENT
(to Prospectus dated January 27, 2025) Belite Bio, Inc 2,272,727 American Depositary Shares
Representing 2,272,727 Ordinary Shares We are offering 2,272,727 American depositary shares, or ADSs, representing 2,272,727 of our ordinary shares, par value US$0.0001 per share, pursuant to this prospectus supplement. Each ADS represents one ordinary share. See “Description of American Depositary Shares” and “Description of Share Capital” in the accompanying prospectus. Our ADSs are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “BLTE.” On December 1, 2025, the last reported sale price of our ADSs on Nasdaq was US$154.02 per ADS. The actual offering price per ADS will be as determined between us and the underwriters at the time of pricing. Our principal executive offices are located at 12750 High Bluff Drive Suite 475, San Diego, CA 92130, and our telephone number is + 1-858-246-6240. Our registered address in the Cayman Islands is located at the offices of Maples Corporate Services Limited at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. We are a holding company incorporated in the Cayman Islands. As a holding company with no material operations of our own, we conduct operations primarily through our direct and indirect wholly owned subsidiaries in the U.S., Australia, Switzerland, Japan, Taiwan, Hong Kong and the People’s Republic of China, or the PRC. Investors purchasing ADSs in this offering are purchasing equity securities of our Cayman Islands holding company, not of our operating subsidiaries. We do not have any substantive operations or employees in the PRC at present and the clinical trials in the PRC in connection with our product candidate are conducted via a contract research organization. However, we may still be subject to certain legal and operational risks associated with our clinical trials conducted in the PRC, including those changes in the legal, political and economic policies of the Chinese government, the relations between China and the United States, or Chinese or U.S. regulations, which may materially and adversely affect our business, financial condition, results of operations and the market price of the ADS